Research progress of mesenchymal stem cell-derived exosomes in the prevention and treatment of retinopathy of prematurity

VernacularTitle:间充质干细胞外泌体防治早产儿视网膜病的研究进展
Author: Zixin LI ¹ ; Xianqiong LUO ¹
Author Information

1. 广东省妇幼保健院新生儿科，广州　511442
Publication Type:Journal Article
Keywords: Mesenchymal stem cell; Retinopathy of prematurity; Exosome; MicroRNA
From: Chinese Journal of Applied Clinical Pediatrics 2025;40(10):796-800
CountryChina
Language:Chinese
Abstract: Retinopathy of prematurity (ROP) is an abnormal proliferative disease of retinal blood vessels that occurs in preterm and low-birth-weight infants.It is a common cause of blindness and visual impairment in children.Current treatments for ROP are associated with various limitations and side effects.Therefore, there is an urgent need to develop more effective prevention and treatment strategies to significantly improve the clinical outcomes of affected children.Mesenchymal stem cell-derived exosomes (MSC-Exo) contain various bioactive factors, including cytokines, proteins, and microRNA (miRNA), which are involved in intercellular communication, immune responses, and other pathophysiological processes.Importantly, miRNA can regulate vascular endothelial cell proliferation and angiogenesis under hypoxic-ischemic conditions.Based on these properties, this article aims to provide a review of the latest research advances on MSC-Exo for the prevention and treatment of ROP, thereby providing a reference basis for the future application of MSC-Exo in managing ROP.